FDA Approves Takeda's Mimrylo (Rusfertide) as First-in-Class Hepcidin Mimetic for Polycythemia Vera

FDA Approves Takeda's Mimrylo (Rusfertide) as First-in-Class Hepcidin Mimetic for Polycythemia Vera

On August 28, 2026, the U.S. Food and Drug Administration (FDA) approved Takeda's Mimrylo (rusfertide) injection for the treatment of erythrocytosis in adults with polycythemia vera (PV). Developed in partnership with Protagonist Therapeutics, Mimrylo represents a major therapeutic breakthrough: it is the first and only hepcidin mimetic peptide therapy approved to control red blood cell production by directly targeting the hepcidin pathway.

Disease Background and Mechanism of Action

Polycythemia vera is a rare, chronic, and progressive blood disorder characterized by the overproduction of red blood cells (erythrocytosis). This excess thickens the blood, increasing the risk of life-threatening cardiovascular complications such as blood clots, stroke, and heart attack. Historically, the primary method of managing hematocrit (red blood cell volume) has been therapeutic phlebotomy (frequent bloodletting), which is physically taxing and fails to address underlying iron regulation.

Mimrylo acts as a synthetic mimetic of hepcidin, the body's natural hormone that regulates iron absorption and distribution. By mimicking hepcidin, Mimrylo limits iron availability for erythropoiesis (red blood cell production), thereby controlling hematocrit levels and significantly reducing or eliminating the need for frequent therapeutic phlebotomy.

Clinical Trial Evidence: The Phase III VERIFY Trial

The FDA approval of Mimrylo was supported by robust clinical data from the pivotal VERIFY Phase III trial, which evaluated the efficacy and safety of rusfertide in patients with PV who required frequent phlebotomies to maintain hematocrit levels below 45%.

• Clinical Response Rate: The trial met its primary endpoint, with Mimrylo demonstrating a clinical response rate of 76.9% compared to 32.9% for the placebo group. This response was defined as maintaining hematocrit control (<45%) without requiring therapeutic phlebotomy during the randomized withdrawal period.
• Safety Profile: Mimrylo was generally well tolerated. The most common adverse events included injection site reactions. The prescribing information carries warnings for new or worsening thrombocytosis (mean platelet increases of approximately 31% from baseline within 4 weeks of starting treatment), which requires regular monitoring.

Market and Paradigm Impact

Mimrylo's approval is expected to fundamentally reshape the treatment paradigm for polycythemia vera, shifting care away from reactive, invasive bloodletting toward proactive, molecularly targeted iron restriction.¹ Takeda has licensed the global commercial rights (excluding certain territories) from Protagonist Therapeutics and is preparing for an immediate U.S. launch.

"Food and Drug Administration (FDA) approved rusfertide (Mimrylo) for adults with polycythemia vera, marking the first approval of a treatment that controls hematocrit by targeting the hepcidin pathway." — Oncology News Central (August 28, 2026)

"MIMRYLO™ is the First and Only Hepcidin Mimetic Peptide Therapy Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera..." — Protagonist Therapeutics Press Release (August 28, 2026)